Introduction
============

Sepsis is the most common cause of death in ICUs \[[@B1]\]. Destruction of intestinal barrier function and increased translocation of bacteria to systemic blood flow can lead to sepsis \[[@B2]\]. Probiotics may have beneficial effects in improvement of critically ill patients by modulating intestinal barrier and reduction of inflammation \[[@B3]\]. The aim of this trial was to determine the effect of probiotic on inflammatory biomarkers and mortality rate of sepsis in critically ill patients in the ICU.

Methods
=======

This double-blind, randomized controlled trial was conducted on 40 critically ill patients admitted to the ICU. They were randomly assigned to receive placebo or probiotic for 7 days. The APACHE score, Sequential Organ Failure Assessment (SOFA) and systemic concentrations of IL-6, procalcitonin (PCT) and protein C were measured before initiation of the study and on days 4 and 7. Also, 28day mortality was evaluated for each patient.

Results
=======

IL-6 and PCT levels decreased and protein C levels increased significantly in probiotic group over the treatment period (*P \<*0.001). There was a significant difference in IL-6, PCT and protein C levels of the 7th day between two groups (*P*= 0.001, 0.006 and \<0.001, respectively). Compared with controls, probiotic was effective in improving APACHE and SOFA scores in 7 days (*P \<*0.001). There was significant difference between the probiotic and control group in the 28-day mortality rate (20% vs. 55% respectively, *P*= 0.048).

Conclusion
==========

Probiotics reduce inflammation and mortality rate in critically ill patients and might be considered as an adjunctive therapy to sepsis.
